Phase 3 Readout~month

Phase 3 Topline: A Double-blind, Placebo-Controlled, Randomized Withdrawal Trial to Evaluate the Efficacy and Safety

TAK overview →Track this catalyst
Indication
Narcolepsy Type 1 (NT1); Narcolepsy With Cataplexy

Other upcoming events for TAK

Phase 2 StartPhase 2 Start: An Open-Label, Single-Arm, Phase 2a Trial to Evaluate the Safety, Tolerability, PK, and Mechanism of
Phase 2 StartPhase 2 Start: A Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase 2 Trial to Evaluate the Safety an
Phase 3 ReadoutPhase 3 Topline: An Open-label, Multicenter Clinical Study on The Long-term Safety and Efficacy of Multiple Treatment
Phase 3 ReadoutPhase 3 Topline: An Open-label, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of 0.05 mg/kg/Day
Phase 3 ReadoutPhase 3 Topline: An Open-Label, Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intravenous (

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

  • 200 free AI credits / month to run live multi-agent analysis
  • Watchlist, catalyst alerts & the biotech event calendar
  • Full pipeline, financials & FDA data on every company
Start Free
    Phase 3 Topline: A Double-blind, Placebo-Controlled, Randomized Withdrawal Trial to Evaluate the Efficacy and Safety — TAK Phase 3 Readout | BioSniper